- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06831552
새로 진단 된 고위험 신경 모세포종이있는 어린이를위한 일반적인 지원 치료에 대한 자원 개입 (RIS)을 지원하기위한 자원 개입의 추가에 대한 무작위 2 상 시험 평가 (RISE in HR NBL)
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.
Participants will be randomized to receive one of the following for 6-months:
- Usual supportive care alone or
- Usual supportive care plus Pediatric RISE
연구 개요
상세 설명
This is a randomized Phase II trial evaluating the addition of the RISE supportive care equity intervention to usual supportive care for poverty-exposed children participants with newly diagnosed high-risk neuroblastoma. Participants will be randomized into one of two groups: Usual supportive care or Pediatric RISE plus usual supportive care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, in-person or virtual appointments, and surveys.
Participation in this research study is expected to last for about 6-months.
It is expected that about 84 participants will take part in this research study.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Kira Bona, MD, MPH
- 전화번호: 617-632-4688
- 이메일: Kira_Bona@dfci.harvard.edu
연구 장소
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
연락하다:
- Katherine Lind, MD
- 이메일: Katherine.Lind@childrenscolorado.org
-
연락하다:
- Navin Pinto, MD
- 이메일: Navin.Pinto@childrenscolorado.org
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- 모병
- Connecticut Children's Medical Center
-
연락하다:
- Andrea Orsey, MD, MSCE
- 전화번호: 860-545-9630
- 이메일: aorsey@connecticutchildrens.org
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Children's Healthcare of Atlanta
-
연락하다:
- Thomas Cash, MD
- 전화번호: 404-785-1200
- 이메일: william.cash@choa.org
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 03079
- 모병
- Dana-Farber Cancer Institute
-
연락하다:
- Kira Bona, MD, MPH
- 전화번호: 203-464-9417
- 이메일: kira.bona@childrens.harvard.edu
-
-
New York
-
New York, New York, 미국, 10027
- 모병
- Columbia University Medical Center
-
연락하다:
- Melissa Beauchemin, MD
-
연락하다:
- Justine Kahn, MD
- 이메일: jk2034@cumc.columbia.edu
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
연락하다:
- Katherine Somers, MD
- 이메일: katherine.somers@cchmc.org
-
연락하다:
- Meera Kotagal, MD
- 이메일: meera.kotagal@cchmc.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
연락하다:
- Rochelle Bagatell, MD
- 전화번호: 267-426-9737
- 이메일: bagatellr@chop.edu
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center
-
연락하다:
- Puja Umaretiya, MD
- 전화번호: (214) 456-2382
- 이메일: puja.umaretiya@utsouthwestern.edu
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Anurekha Hall, MD
- 전화번호: 206-987-2106
- 이메일: anurekha.hall@seattlechildrens.org
-
연락하다:
- Kristine Karvonen, MD
- 이메일: Kristine.Karvonen@seattlechildrens.org
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.
- Patient newly diagnosed with high-risk neuroblastoma
- Patient has established care at study site and initiated cancer-directed therapy
- Patient has not yet initiated Induction Cycle 3
- Patient aged 0-17 years at the time of consent
- Parent/guardian screened positive for self-reported low-income (<200% Federal Poverty) *
- Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
- Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
- Patients of all languages are eligible to participate
Exclusion Criteria:
- Foreign national family receiving care as an Embassy-pay patient.
- Child or household member receiving SSI
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 1: RISE Intervention + Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and Household Material Hardship (HMH) severity score. Participant parents/guardians will complete:
|
Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
다른 이름들:
|
|
간섭 없음: Arm 2: Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity score. Participant parents/guardians will complete:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Household Material Hardship (HMH) Score Reduction Rate
기간: Baseline (T1) and 6-months (end-intervention; T3)
|
HMH score reduction rate is defined as the proportion of patients achieving at least 1 domain reduction in (food, housing, utility or transportation insecurity). HMH scores range from 0 to 4, with scores of 0 indicating no hardship (unexposed) and scores of 1-4 indicating the presence of hardship (exposed). Patients who are unexposed to HMH at baseline (HMH score of 0) are excluded from the analysis. |
Baseline (T1) and 6-months (end-intervention; T3)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pediatric-Modified Comprehensive Score for Financial Toxicity (COST)
기간: 3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
Financial toxicity will be assessed with the 12-item modified COST measure. Each item is rated on a 0-4 scale, yielding a total score range of 0-48, with higher scores indicating better financial well-being. The final COST score will be calculated per established methods. A change of approximately 5 points is considered a minimally important difference (MID), representing a clinically meaningful change in financial toxicity. |
3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
|
Parent Psychological Distress (Kessler-6) Score Change from Baseline to 6 Months
기간: Baseline (T1) and 6-months (end-intervention; T3)
|
Psychological distress will be assessed using the 6-item Kessler-6 scale. The scale includes 6 items scored from 0 ('none of the time') to 4 ('all of the time'), yielding a total score ranging from 0 to 24, with higher scores indicating greater psychological distress. A reduction in scores of approximately 2.8 points is considered a minimally important difference (MID), representing a clinically meaningful improvement in psychological distress. |
Baseline (T1) and 6-months (end-intervention; T3)
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Abilities Score Change from Baseline to 6 Months
기간: Baseline (T1) and 6-months (end-intervention; T3)
|
The PROMIS Applied Cognition-Abilities short form is an 8-item measure assessing subjective learning and memory, attention and concentration, executive function, and processing speed. Responses are scored on a scale of 1-5, and the total score is converted to a T-score with a mean of 50 and a standard deviation (SD) fixed at 10. Higher scores suggest better perceived cognitive function. |
Baseline (T1) and 6-months (end-intervention; T3)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Kira Bona, MD, MPH, Dana-Farber Cancer Institute
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 24-600
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Dr. Kira Bona. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 공유 기간
Data can be shared no earlier than 1 year following the date of publication
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .